Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 2/2016

01.04.2016 | leitlinien für die praxis

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2

Grundsatz Statement

verfasst von: Martin Clodi, Heidemarie Abrahamian, Heinz Drexel, Peter Fasching, Bernhard Föger, Claudia Francesconi, Friedrich Hoppichler, Susanne Kaser, Alexandra Kautzky-Willer, Monika Lechleitner, Bernhard Ludvik, Rudolf Prager, Elke Fröhlich-Reiterer, Michael Roden, Christoph Säly, Guntram Schernthaner, Harald Sourij, Hermann Toplak, Thomas C. Wascher, Raimund Weitgasser

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Die Hyperglykämie ist wesentlich an der Entstehung mikro- und makrovaskulärer Spätkomplikationen bei an Diabetes mellitus Typ 2 erkrankten Patienten/Patientinnen beteiligt. Während Lebensstilmaßnahmen die Eckpfeiler jeder Diabetestherapie bleiben, benötigen im Verlauf die meisten Patienten/Patientinnen mit Typ 2 Diabetes eine medikamentöse Therapie. Bei der Definition individueller Behandlungsziele stellen die Therapiesicherheit bzw. die Effektivität der Therapie die wichtigsten Faktoren dar. In dieser Leitlinie haben wir die rezenten evidenzbasierten Daten für die klinische Praxis zusammengestellt.
Literatur
1.
Zurück zum Zitat Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care. 2015;38:140–149. CrossRefPubMed Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care. 2015;38:140–149. CrossRefPubMed
2.
Zurück zum Zitat Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. CrossRef Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. CrossRef
3.
Zurück zum Zitat UK prospective diabetes study (ukpds) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (ukpds 33). Lancet. 1998;352:837–853. CrossRef UK prospective diabetes study (ukpds) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (ukpds 33). Lancet. 1998;352:837–853. CrossRef
4.
Zurück zum Zitat Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–1693. CrossRefPubMed Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–1693. CrossRefPubMed
5.
Zurück zum Zitat Schernthaner G, Mogensen CE, Schernthaner GH. The effects of glp-1 analogues, dpp-4 inhibitors and sglt2 inhibitors on the renal system. Diabet vasc dis res. 2014;11:306–323. CrossRef Schernthaner G, Mogensen CE, Schernthaner GH. The effects of glp-1 analogues, dpp-4 inhibitors and sglt2 inhibitors on the renal system. Diabet vasc dis res. 2014;11:306–323. CrossRef
6.
Zurück zum Zitat Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. CrossRefPubMed Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. CrossRefPubMed
7.
Zurück zum Zitat UK prospective diabetes study (ukpds) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (ukpds 34). Lancet. 1998;352:854–865. CrossRef UK prospective diabetes study (ukpds) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (ukpds 34). Lancet. 1998;352:854–865. CrossRef
8.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. CrossRefPubMed
9.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. CrossRefPubMed Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. CrossRefPubMed
10.
Zurück zum Zitat Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139. CrossRefPubMed Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139. CrossRefPubMed
11.
Zurück zum Zitat Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288–2296. doi: 10.1093/eurheartj/ehv239. CrossRefPubMed Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288–2296. doi: 10.1093/eurheartj/ehv239. CrossRefPubMed
12.
Zurück zum Zitat Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): A randomised controlled trial. Lancet. 2005;366:1279–1289. CrossRefPubMed Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): A randomised controlled trial. Lancet. 2005;366:1279–1289. CrossRefPubMed
13.
Zurück zum Zitat Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the proactive (proactive 05) study. J Am Coll Cardiol. 2007;49:1772–1780. CrossRefPubMed Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the proactive (proactive 05) study. J Am Coll Cardiol. 2007;49:1772–1780. CrossRefPubMed
14.
Zurück zum Zitat Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from proactive (prospective pioglitazone clinical trial in macrovascular events 04). Stroke. 2007;38:865–873. CrossRefPubMed Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from proactive (prospective pioglitazone clinical trial in macrovascular events 04). Stroke. 2007;38:865–873. CrossRefPubMed
15.
Zurück zum Zitat Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA. 2007;298:1180–1188. CrossRefPubMed Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA. 2007;298:1180–1188. CrossRefPubMed
16.
Zurück zum Zitat Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, BARI 2D Study Group, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–2515. CrossRefPubMed Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, BARI 2D Study Group, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–2515. CrossRefPubMed
17.
Zurück zum Zitat Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–16. CrossRefPubMed Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–16. CrossRefPubMed
18.
Zurück zum Zitat Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, The ORIGIN Trial Investigators, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328. CrossRefPubMed Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, The ORIGIN Trial Investigators, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328. CrossRefPubMed
Metadaten
Titel
Antihyperglykämische Therapie bei Diabetes mellitus Typ 2
Grundsatz Statement
verfasst von
Martin Clodi
Heidemarie Abrahamian
Heinz Drexel
Peter Fasching
Bernhard Föger
Claudia Francesconi
Friedrich Hoppichler
Susanne Kaser
Alexandra Kautzky-Willer
Monika Lechleitner
Bernhard Ludvik
Rudolf Prager
Elke Fröhlich-Reiterer
Michael Roden
Christoph Säly
Guntram Schernthaner
Harald Sourij
Hermann Toplak
Thomas C. Wascher
Raimund Weitgasser
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-016-0991-z

Weitere Artikel der Sonderheft 2/2016

Wiener klinische Wochenschrift 2/2016 Zur Ausgabe

leitlinien für die praxis

Diabetischer Fuß